Innovent Biologics' Seven Innovative Drugs Added to China's 2026 Reimbursement List

MT Newswires Live11-16 09:52

Innovent Biologics' (HKG:1801) seven innovative drugs have been included in China's 2026 National Reimbursement Drug List, which will take effect on Jan. 1, 2027, according to a Sunday Hong Kong bourse filing.

Four products, including mazdutide and PECONDLE, secured first-time inclusion. Two others, TYVYT and Jaypirca, received coverage for additional indications, while SINTBILO retained its reimbursement status following renewal.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment